AbbVie Appears Ready To Move Higher
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
pharmaphorum1d
AbbVie gets continuous Parkinson's drug over the line in US
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...
New Study Uncovers a Shocking Side Effect of a Parkinson’s Drug
A new study reveals that entacapone, a drug used to treat Parkinson’s disease, significantly disrupts the gut microbiome by ...
pharmaphorum2d
AbbVie launches pump-based Parkinson’s drug in EU
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight
According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...
Yahoo Finance11d
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
In October 2024, the FDA approved AbbVie’s Vyalev for treating motor fluctuations in the adult population with advanced Parkinson’s disease. "FDA approves AbbVie’s Emblaveo for intra ...
Crain's Chicago Business9d
AbbVie inks another billion-dollar oncology deal
AbbVie is collaborating with a clinical-stage biotech company that's developing tumor-activated immuno-oncology therapies it hopes will not wreak havoc on the entire body. Under the terms, which ...
The Motley Fool6d
Is AbbVie Stock a Buy Now?
AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...